Draft guidance from UK's NICE rejects Bristol-Myers Orencia
US drug major Bristol-Myers Squibb (NYSE: BMY) says that the UK’s drug watchdog the National Institute for Health and Clinical Excellence (NICE ) did not recommend Orencia (abatacept) as a second-line treatment for moderate to severe rheumatoid arthritis in patients who have inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDS).
Currently, the NICE recommends four drugs for second-line use in rheumatoid arthritis including Abbott’s Humira (adalimumab), Pfizer’s Enbrel (etancercept), Merck & Co’s Remicade (infliximab) and UCB’s Cimzia (certolizumab). Analysts at Credit Suisse have a net present value for Orencia of $3.26/share or 9.4% of total NPV for B-MS.
Abatacept is not cost-effective, says agency
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze